Galecto Inc. Unveils Acquisition Details and Pipeline Milestones Following Damora Therapeutics Deal

Reuters2025-11-10

<a href="https://laohu8.com/S/GLTO">Galecto Inc.</a> Unveils Acquisition Details and Pipeline Milestones Following Damora <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Deal

Galecto Inc. has announced the acquisition of Damora Therapeutics in a stock-for-stock transaction, exchanging all of Damora's outstanding equity for a combination of Galecto common stock and newly created Series C convertible preferred stock. Concurrent with the acquisition, Galecto completed a $285 million private placement led by Fairmount and a syndicate of biotechnology investors. The proceeds are expected to advance Damora's pipeline, including proof-of-concept data for DMR-001 and DMR-002 and an IND filing for DMR-003, with a projected cash runway into 2029. The leadership team will include Hans Schambye, Matthew Kronmiller, Lori Firmani, and Garrett Winslow, with new board members from Fairmount joining the existing board. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galecto Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582871283?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582871283","market":"fut","top_or_hot":-1,"title":"Galecto Inc. Unveils Acquisition Details and Pipeline Milestones Following Damora Therapeutics Deal","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a> Unveils Acquisition Details and Pipeline Milestones Following Damora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Deal\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Galecto Inc. has announced the acquisition of Damora Therapeutics in a stock-for-stock transaction, exchanging all of Damora's outstanding equity for a combination of Galecto common stock and newly created Series C convertible preferred stock. Concurrent with the acquisition, Galecto completed a $285 million private placement led by Fairmount and a syndicate of biotechnology investors. The proceeds are expected to advance Damora's pipeline, including proof-of-concept data for DMR-001 and DMR-002 and an IND filing for DMR-003, with a projected cash runway into 2029. The leadership team will include Hans Schambye, Matthew Kronmiller, Lori Firmani, and Garrett Winslow, with new board members from Fairmount joining the existing board. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galecto Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Galecto Inc. Unveils Acquisition Details and Pipeline Milestones Following Damora Therapeutics Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGalecto Inc. Unveils Acquisition Details and Pipeline Milestones Following Damora Therapeutics Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 21:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a> Unveils Acquisition Details and Pipeline Milestones Following Damora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Deal\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Galecto Inc. has announced the acquisition of Damora Therapeutics in a stock-for-stock transaction, exchanging all of Damora's outstanding equity for a combination of Galecto common stock and newly created Series C convertible preferred stock. Concurrent with the acquisition, Galecto completed a $285 million private placement led by Fairmount and a syndicate of biotechnology investors. The proceeds are expected to advance Damora's pipeline, including proof-of-concept data for DMR-001 and DMR-002 and an IND filing for DMR-003, with a projected cash runway into 2029. The leadership team will include Hans Schambye, Matthew Kronmiller, Lori Firmani, and Garrett Winslow, with new board members from Fairmount joining the existing board. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galecto Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLTO","symbol_name":"Galecto Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL30bwXD:1","article_id":"2582871283","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582871283","pubTimestamp":1762781217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Galecto Inc. has announced the acquisition of Damora Therapeutics in a stock-for-stock transaction, exchanging all of Damora's outstanding equity for a combination of Galecto common stock and newly created Series C convertible preferred stock. Concurrent with the acquisition, Galecto completed a $285 million private placement led by Fairmount and a syndicate of biotechnology investors. The proceeds are expected to advance Damora's pipeline, including proof-of-concept data for DMR-001 and DMR-002 and an IND filing for DMR-003, with a projected cash runway into 2029. The leadership team will include Hans Schambye, Matthew Kronmiller, Lori Firmani, and Garrett Winslow, with new board members from Fairmount joining the existing board. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLTO":"Galecto Inc.","BK4139":"生物科技"},"translate_title":"Galecto Inc.在Damora Therapeutics交易后公布了收购细节和管道里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLTO":0.9},"content_text":"Galecto Inc. Unveils Acquisition Details and Pipeline Milestones Following Damora Therapeutics Deal\n    \n\n        Galecto Inc. has announced the acquisition of Damora Therapeutics in a stock-for-stock transaction, exchanging all of Damora's outstanding equity for a combination of Galecto common stock and newly created Series C convertible preferred stock. Concurrent with the acquisition, Galecto completed a $285 million private placement led by Fairmount and a syndicate of biotechnology investors. The proceeds are expected to advance Damora's pipeline, including proof-of-concept data for DMR-001 and DMR-002 and an IND filing for DMR-003, with a projected cash runway into 2029. The leadership team will include Hans Schambye, Matthew Kronmiller, Lori Firmani, and Garrett Winslow, with new board members from Fairmount joining the existing board. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galecto Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582871283","isCrawlerRequest":true}